The Memorial Delirium Assessment Scale
The Memorial Delirium Assessment Scale
复制标题
DOI：
10.1016/s0885-3924(96)00316-8
复制
发表时间：
1997-03-01
影响因子：
4.7
通讯作者：
Passik, S
中科院分区：
文献类型：
--
作者：
Breitbart, W;Rosenfeld, B;Passik, S
我们进行了两项研究，医学住院的癌症和获得性免疫缺陷综合征（AIDS）患者，以评估谵妄严重程度的新措施，记忆谵妄评估量表（MDAS）的可靠性和有效性。第一项研究使用了多名评估者，他们对33名患者联合使用MDAS，其中17名患者符合DSM III-R/DSM IV谵妄标准，8名患者符合另一种认知障碍（例如痴呆）的诊断标准，8名患者患有非认知精神障碍（例如适应障碍）。结果表明MDAS（0.92）和单个MDAS项目（范围从0.64到0.99）的评分者间可靠性水平很高，并且内部一致性水平很高（系数α = 0.91）。谵妄患者与其他认知功能障碍或无认知功能障碍患者的MDAS评分差异有统计学意义（P < 0.0002）。第二项研究比较了由一名临床医生对51名患有癌症和艾滋病的医学住院谵妄患者的MDAS评分与由第二名临床医生对谵妄（谵妄评分量表，临床医生对谵妄严重程度的评分）和认知功能（简易精神状态检查）的其他几项测量的评分。结果表明MDAS评分与谵妄评定量表（r = 0.88，P < 0.0001）、简易精神状态检查（r=-0.91，P < 0.0001）和临床医生对谵妄严重程度的总体评定（r = 0.89，P < 0.0001）评分之间存在高度相关性。因此，我们的研究结果表明，MDAS是一个简单，可靠的工具，用于评估谵妄的严重程度之间的医学疾病的人群，可以可靠地评分由多个评分。MDAS与谵妄和认知障碍的现有测量高度相关，但在临床研究中经常需要重复评估时，它提供了优于这些工具的几个优势。(C)美国癌症疼痛缓解委员会，1997年。
We conducted two studies with medically hospitalized cancer and acquired immunodeficiency syndrome (AIDS) patients to assess the reliability and validity of a new measure of delirium severity, the Memorial Delirium Assessment Scale (MDAS). The first study used multiple raters who jointly administered the MDAS to 33 patients, 17 of whom met DSM III-R/DSM IV criteria for delirium, 8 met diagnostic criteria for another cognitive impairment disorder (for example, dementia), and 8 had non-cognitive psychiatric disorders (for example, adjustment disorder). Results indicate high levels of inter-rater reliability for the MDAS (0.92) and the individual MDAS items (ranging from 0.64 to 0.99), as well as high levels of internal consistency (coefficient alpha = 0.91). Mean MDAS ratings differed significantly between delirious patients and the comparison sample of patients with other cognitive impairment disorders or no cognitive impairment (P < 0.0002). The second study compared MDAS ratings of 51 medically hospitalized delirious patients with cancer and AIDS made by one clinician to ratings on several other measures of delirium (Delirium Rating Scale, clinician's ratings of delirium severity) and cognitive functioning (Mini-Mental State Examination) made by a second clinician. Results demonstrated a high correlation between MDAS scores and ratings on the Delirium Rating Scale (r = 0.88, p < 0.0001, the Mini-Mental State Examination (r= -0.91, P < 0.0001), and clinician's global ratings of delirium severity (r = 0.89, P < 0.0001). Thus, our findings indicate that the MDAS is a brief, reliable tool for assessing delirium severity among medically ill populations that can be reliably scored by multiple raters. The MDAS is highly correlated with existing measures of delirium and cognitive impairment, yet offers several advantages over these instruments for repeated assessments which are often necessary in clinical research. (C) U.S. Cancer Pain Relief Committee, 1997.